Biodextris
A project-based approach to biologics CDMO collaboration
October 24, 2023
In the landscape of the biopharmaceutical industry, the partnership between a biopharma sponsor and its biologics Contract Development and Manufacturing Organization (biologics CDMO) has become more than a simple business arrangement and has transformed into a strategic collaboration characterized by flexibility and adaptability.
Historically, biopharma companies have had to contract very large projects out to biologics CDMO meaning they would commit large financial and organisational resources, which did not always match investment cycles. Today, the industry and its biopharma CDMOs are recognizing the benefits of segmenting projects and costs,
aligning them with funding phases and thus optimizing resources while fostering innovation.
Biodextris: at the heart of a multi-expertise CDMO organization
With extensive development and manufacturing capacities, biologics CDMO Biodextris has accompanied this change with strong, project-based partnerships
with the biopharma industry. As part of the Clean Biologics group, Biodextris is also at the heart of a multi-expertise organization, thus enhancing the capacity to coordinate overall biopharma CDMO capacities
while keeping a segmented approach.
Aligning organisational resources with funding cycles to mitigate risk and foster innovation
Biopharma projects typically go through several funding cycles, covering discovery and R&D, clinical trials and commercialization, and which require support from biopharma CDMOs and CROs. This includes sometimes long analytical, development and biomanufacturing phases requiring a sizable financial commitment. A flexible approach to biologics CDMO collaboration aligns costs with these funding phases
ensuring that financial resources are used efficiently.
Additionally, this strategy contributes to overall risk mitigation: the development cycle of a biopharma substance is rife with uncertainties, including regulatory changes, market dynamics, and technical advancements. Flexibility in biologics CDMO partnerships allows biopharma companies to adapt to these pitfalls and hurdles more efficiently.
With a keen understanding of the biopharma dynamics and its privileged position within a biologics CDMO group,
Biodextris optimizes resources for sponsors by reducing organisational burdens: this leaves our partners with more time and resources for their core and strategic activities
including discovery, R&D and business development.
With Biodextris, your project is overseen by dedicated project managers with extensive hands-on experience, saving you time and enhancing your experience.
Leave A Comment
Search
Recent Posts
Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman & Chief Commercial Officer Who: Dr. Behzad Mahdavi, Ph.D., MBA, NACD.DC — a biopharma industry veteran with over 25 years of senior leadership experience in CDMO and CRO sectors, including roles at Lonza and Catalent. What: He has been appointed Executive Chairman and will additionally serve as Chief Commercial Officer at Biodextris. Why: Dr. Mahdavi will spearhead the company’s global commercial expansion, leveraging his expertise in commercial innovation and international market development About Biodextris: Headquartered in Laval (Montréal), Québec, Biodextris is a rising Contract Development & Manufacturing Organization (CDMO) specializing in biologics and vaccine development, rooted in the legacy of GSK’s biologics and supported by ArchiMed private equity. For full details, you can read the original PR Newswire article here: https://www.prnewswire.com/news-releases/biodextris-appoints-dr-behzad-mahdavi-as-executive-chairman-to-lead-global-commercial-expansion-302472664.html
Learn about the strategic partnership between Aramis Biotechnologies and Biodextris to advance vaccine and biologics development.
Clean Biologics acquires Biodextris—bringing together expertise in biologics manufacturing and accelerating growth in CDMO services.
Biodextris inaugure de nouvelles installations à Laval pour renforcer son expertise en développement biologique.
Biodextris inaugurates its new Laval facility in Biotech City, expanding its capabilities in biologics development and manufacturing.
Discover Biodextris' new cGMP biomanufacturing and analytical facility. Check out our state-of-the-art capabilities.
Share Posts